[02359.HK H shares fell more than 8 per cent to single digits in the first quarter] FAP reported that as of press time, Pharmaceutical Kant () fell 8.10 per cent. Yesterday night the company announced its results for the first quarter of 2023, with operating income of about 8.964 billion yuan (the same unit below), an increase of 5.77% over the same period last year, and net profit of about 2.168 billion yuan, an increase of 31.97% over the same period last year. Revenue growth slowed compared with the 71.84% increase in revenue for the whole of last year. It is also the first time that revenue growth in a single quarter has slowed to single digits since Yao Ming Kant went public in 2018.